Stocktoria

GERON CORP GERN

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 1996-07-31 · LEI

GERON CORP financials (annual)

Revenue
$6.2M $1.1M $1.1M $460000 $253000 $1.4M $596000 $237000 2016201720182019202020212022202320242025
Net income
-$29.5M -$27.9M -$27.0M -$68.5M -$75.6M -$116.1M -$141.9M -$184.1M -$174.6M -$83.5M 2016201720182019202020212022202320242025
Free cash flow
-$18.4M -$21.0M -$44.2M -$67.1M -$95.8M -$127.8M -$168.6M -$219.3M 2016201720182019202020212022202320242025

Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$237,000$596,000$1.4M$253,000$460,000$1.1M$1.1M$6.2M
SG&A expense$159.3M$145.7M$69.1M$43.6M
Operating income-$68.6M-$173.7M-$193.9M-$138.6M-$114.0M-$76.9M-$72.5M-$31.1M-$29.3M-$30.6M
Interest expense$18.5M$8.3M$6.9M$3.7M$760,000
Income tax$75,000$449,000$22,000
Net income-$83.5M-$174.6M-$184.1M-$141.9M-$116.1M-$75.6M-$68.5M-$27.0M-$27.9M-$29.5M
EPS (diluted)$-0.13$-0.27$-0.32$-0.37$-0.35$-0.28$-0.18$-0.19
Operating cash flow-$111.0M-$218.6M-$167.7M-$127.4M-$95.6M-$66.7M-$43.8M-$21.0M-$20.6M-$18.4M
Free cash flow-$219.3M-$168.6M-$127.8M-$95.8M-$67.1M-$44.2M-$21.0M-$18.4M
Cash & equivalents$77.6M$79.0M$70.0M$56.8M$34.9M$9.9M$13.6M$10.6M$16.3M$12.8M
Inventory$116.6M$38.7M
Total assets$570.5M$593.8M$394.1M$190.6M$226.0M$270.7M$165.5M$185.3M$110.3M$130.2M
Total liabilities$344.7M$313.5M$146.1M$110.6M$99.6M$59.8M$30.4M
Shareholders' equity$225.9M$280.3M$247.9M$80.0M$126.4M$210.9M$135.2M$177.7M$103.8M$122.4M

Growth · year-over-year · Revenue CAGR -37.2%

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue growth-60.2%-57.2%+450.6%-45.0%-56.8%+0.1%-82.7%-83.1%
Net income growth-64310.9%

Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.